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Overexpression of survivin in primary ATL cells and sodium arsenite induces
apoptosis by down-regulating survivin expression in ATL cell lines
Xiao-Fang Che, Chun-Lei Zheng, Satsuki Owatari, Masato Mutoh, Takenari Gotanda, Hei-Cheul Jeung, Tatsuhiko Furukawa, Ryuji Ikeda,
Masatatsu Yamamoto, Misako Haraguchi, Naomichi Arima, and Shin-ichi Akiyama
Patients with acute- or lymphoma-type
adult T-cell leukemia (ATL) have a poor
outcome because of the intrinsic drug
resistance to chemotherapy. Protection
from apoptosis is a common feature in-
volved in multidrug-resistance of ATL.
IAP (inhibitor of apoptosis) family pro-
teins inhibit apoptosis induced by a vari-
ety of stimuli. In this study, we investi-
gated the expression of IAP family
members (survivin, cIAP1, cIAP2, and
XIAP) in the primary leukemic cells from
patients with ATL. We found that survivin
was overexpressed in ATL, especially in
acute-type ATL. Sodium arsenite was
shown to down-regulate the expression
of survivin at both the protein and RNA
levels in a time- and dose-dependent man-
ner, thus inhibiting cell growth, inducing
apoptosis, and enhancing the caspase-3
activity in ATL cells. Nuclear factor-B
(NF-B) enhances the transcriptional ac-
tivity of survivin. Sodium arsenite sup-
pressed the constitutive NF-B activation
by preventing the IB- degradation and
the nuclear translocation of NF-B. These
findings suggest that survivin is an impor-
tant antiapoptotic molecule that confers
drug resistance on ATL cells. Sodium
arsenite was shown to down-regulate the
expression of survivin through the NF-B
pathway, thus inhibiting cell growth and
promoting apoptosis of ATL cells. (Blood.
2006;107:4880-4887)
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Introduction
Adult T-cell leukemia (ATL) is an aggressive malignancy of CD4
T cells associated with human T-cell leukemia virus type 1
(HTLV-1) infection.1 There is evidence suggesting that HTLV-1
viral Tax protein activates the expression of a number of cellular
genes, such as growth factors, growth factor receptors, and
oncogenes, through the induction of transcription factors, such as
nuclear factor-B (NF-B),2 cyclic adenosine monophosphate
(cAMP) response element binding protein (CREB)/AP-1 transcrip-
tion factor (ATF),3 and serum response factor (SRF).4 However, the
presence of tax gene expression has not yet been clearly established
in freshly isolated ATL cells; moreover, defective viruses, which
cannot produce Tax, have been observed in ATL cells, thus
suggesting that the tax gene is necessary for the initial stages of
leukemogenesis, but it is not essential for the late stage of
leukemia.5 As suggested by the multistep model of tumorigenesis,6
mutations of various genes are considered to contribute to
leukemogenesis.
ATL is divided into 4 clinical subtypes: acute, lymphoma,
chronic, and smoldering.7 Chronic- and smoldering-type ATLs
have a mild clinical course and do not require treatment with
intensive chemotherapy. Acute- and lymphoma-type ATLs require
intensive chemotherapy, and the median survival period is less than
1 year because of resistance to chemotherapy. Several mechanisms
are involved in the multidrug resistance of ATL, including the
overexpression of P-glycoprotein (P-gp),8 multidrug resistance
protein 1 (MRP1),9 and lung resistance-related protein (LRP).10
Accumulating evidence suggests that the activation of NF-B is a
critical process in the inhibition of apoptosis and resistance to
chemotherapy.11
Survivin, cIAP1, cIAP2, and XIAP belong to the IAP (inhibitor
of apoptosis) family, which is defined by 1 or more repeats of a
highly conserved 70–amino acid domain called the baculovirus
IAP repeat (BIR) located at the amino-terminus. IAP family
proteins directly bind and inhibit certain caspases and also inhibit
apoptosis induced by a variety of stimuli.12 Previous studies have
revealed that several IAPs, such as survivin, NAIP, and XIAP, were
overexpressed in acutel myeloid leukemia (AML).13 Survivin was
overexpressed in chronic lymphocytic leukemia (CLL) and ATL.14,15
The IAPs are probably involved in the drug resistance in leukemia.
Survivin was also demonstrated to be an unfavorable prognostic
factor in leukemia, oral squamous cell carcinoma, and bladder
cancer.16-19 Among the known IAPs, survivin was prominently and
consistently expressed in ATL and the expression level of the
survivin mRNA has correlated with a shorter survival of the
patients.15 However, the expression of other IAP members such as
IAP1, IAP2, and XIAP in ATL is still uncertain. Ishitsuka and
colleagues showed that arsenic trioxide (As2O3) has a therapeutic
potential for the treatment of ATL.20 They suggested that As2O3
induced apoptosis of ATL cells by the destruction of the Bcl-2
protein and the enhancement of the Bak protein production.21
In the present study, we investigated the expression levels of the
members of the IAP family in primary ATL cells. We thus found
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survivin to be overexpressed in ATL while sodium arsenite
inhibited cell growth and apoptosis through the down-regulation
of survivin.
Patients, materials, and methods
Patients
Between July 1999 and July 2003, we studied 38 patients with ATL (Table
1) consisting of 18 men and 20 women with a median age of 62 years
(range, 21-87 years). According to previously reported diagnostic criteria,7
23 of these patients had acute-type ATL, 12 had chronic-type ATL, and 3
had smoldering-type ATL. The performance status (PS) was based on the
5-grade scale of the World Health Organization. Seventeen patients had a
PS of 0; 8 patients had a PS of 1; 6 patients had a PS of 2; 3 patients had a PS
of 3; and 4 patients had a PS of 4. During this study, we treated patients with
acute ATL with combination chemotherapy regimens such as a response-
oriented multidrug protocol; a cyclophosphamide, DOX, vincristine, and
prednisone protocol; or an LSG15 protocol. None of the patients with
chronic and smoldering ATL required treatment with intensive chemo-
therapy. Approval for this study was obtained from the Kagoshima
University institutional review board. Informed consent was provided
according to the Declaration of Helsinki.
Reagents and antibodies
RPMI 1640 was purchased from Nissui Seiyaku (Tokyo, Japan). Fetal calf
serum (FCS) was obtained from Equitech-Bio (Kerrville, TX). Sodium
arsenite (NaAsO2, AsIII) and Ac-DEVD-MCA (Ac-Asp-Glu-Val-Asp-
MCA) were obtained from Wako Pure Chemical Industries (Osaka, Japan).
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) was
obtained from Sigma Chemical (St Louis, MO).
Antibodies against NF-B (polyclonal antibody p65 and monoclonal
antibody p50) and monoclonal antibodies against Bcl-2, PARP, and IB-
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). A
monoclonal antibody against -tubulin was from Oncogene (Boston, MA).
A polyclonal antibody against survivin, MP001, was prepared in our
laboratory. MRPm6, a monoclonal antibody against MRP1, was purchased
from Progen Biotechnick (Heidelberg, Germany).
Cell lines and cell cultures
The human ATL cell line MT2 is derived from normal human leucocytes
transformed by the leukemic T cells of a patient with ATL; S1T comes from
HTLV-1–infected CD4 T cells with no Tax expression that are derived
from a patient with ATL. The acute T-cell lymphoma cell line Jurkat was
used as a control. The cell lines were grown in RPMI 1640 containing 10%
FCS, 2 mM glutamine, and 100 U/mL penicillin at 37°C in a 5% CO2
humidified atmosphere.
cDNA synthesis
Peripheral blood mononuclear cells were separated by Ficoll-Conray
(Immuno-Biological, Gunma, Japan) density gradient centrifugation and
stored at 80°C until use for RNA or protein extraction. The total RNA
from peripheral blood mononuclear cells and the cultured cells was isolated
using TRIzol reagent (Invitrogen, Carlsbad, CA). RNA (1 g) was reverse
transcribed using a first-strand cDNA synthesis kit (ReverTra Ace ;
TOYOBO, Osaka, Japan).
Reverse transcription–PCR
The resulting first-strand cDNA (1 L) was used for each polymerase chain
reaction (PCR). The human survivin primers were as follows: forward,
5-GAT TTG AAT CGC GGG ACC CGT TG-3; and reverse, 5-TCAAGA
CAA AAC AGG AGC ACA GT-3. The primers of -actin for internal
control were as follows: forward, 5-CAG CTT CGG AAC AAG AGA
CC-3; and reverse, 5-GTC CGA TGA TTC CTG CTG AT-3.
The PCR amplification mixture was adjusted to a final volume of 20 L.
Twenty-five cycles were performed at 94°C for 30 seconds for denaturation,
58°C for 30 seconds for annealing, and 72°C for 1 minute for extension.
The PCR products were separated on 1% agarose gel and then were stained
with ethidium bromide.
Real-time reverse transcription–PCR quantification
The resulting first-strand cDNA (1 L) was assayed by real-time reverse
transcription (RT)–PCR (PRISM 7900HT; Applied Biosystems, Foster
City, CA) according to a technical brochure of the company. The sets of
primers and TaqMan probes were designed with the primer design software
Primer Express version 2.0 (Applied Biosystems). The primers and TaqMan
probes were as follows: The sequence of the forward primer for survivin
mRNA was 5-TTC AAG AAC TGG CCC TTC TTG-3, and that of the
reverse primer was 5-TGG CTC CCA GCC TTC CA-3; the TaqMan
probe was FAM-CCT GCA CCC CGG AGC GGA T-TAMRA. For XIAP
mRNA, the forward primer was 5-GCC TTA GAC AGG CCA TCT GAG
A-3, and the reverse primer was 5-TTC CTC GGG TAT ATG GTG TCT
GAT-3; the TaqMan probe was FAM-TGC AGA CTA TCT TTT GAG
AAC TGG GCA GGT-TAMRA. For cIAP1 mRNA, the forward primer was
5-CAG ACA CAT GCA GCT CGA ATG-3, and the reverse primer was
5-AAG CCA CCA TCA CAA CAA AAG-3; the TaqMan probe was
FAM-TGT TCC AGT TCA GCC TGA GCA GCT TG-TAMRA. The
forward primer for GAPDH mRNA was 5-GAA GGT GAA GGT CGG
AGT-3, and the reverse primer was 5-GAA GAT GGT GAT GGG ATT
TC-3; the TaqMan probe was FAM-CAA GCT TCC CGT TCT CAG
CC-TAMRA. The conditions for the 1-step RT-PCR were as follows: 2
minutes at 50°C and 10 minutes at 95°C, and then 40 cycles of amplification
for TaqMan Universal PCR Master Mix (Roche, Branchburg, NJ) at 95°C
for 15 seconds and annealing and extension at 60°C for 1 minute. Human
GAPDH was used for normalization. Quantification of the target gene
expression was done using the comparative cycle threshold method
according to the instructions of the manufacturer (Applied Biosystems). All
experiments were performed in triplicate for each data point. Each
quantitation was performed with the standard curve method.
Protein extraction and Western blotting
After treatment with various concentrations of sodium arsenite, cells were
harvested and lysed with RIPA buffer (50 mM Tris-HCl [pH 7.4], 150 mM
Table 1. Patient characteristics
Data
No. patients 38
No. men/no. women 18/20





WBC, median  109/L (range) 8.4 (1.5-47.94)
Abnormal lymphocytes, median % (range) 15 (1-78)














LDH indicates lactose dehydrogenase; PR, partial response; CR, complete
response; and PD, progressive disease.
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NaCl, 1 mM EGTA, 1 mM EDTA, 20 mM NaF, 100 mM Na3VO4, 0.5%
Nonidet P-40 [NP-40], 1% Triton X-100, and 1 mM PMSF). The lysates
were passed through a 21-gauge needle to break up the cell aggregates, and
were cleared by centrifugation at 14 000g for 15 minutes at 4°C; the
supernatant (total cell lysate) was immediately used or stored at 80°C
until use.
For the detection of NF-B, the cells were washed with ice-cold
phosphate-buffered saline (PBS) and lysed in 400 L lysis buffer (buffer A,
containing 10 mM HEPES [pH 7.9], 10 mM KCl, 0.2 mM EDTA, 1 mM
DTT, 0.5 mM PMSF, and 0.6% NP-40). The lysates were centrifuged at
250g for 10 minutes. The supernatant was collected as the cytosolic
fraction. The pellets containing the nuclei were washed in buffer A without
NP-40 and then were resuspended in 50 L nuclear lysis buffer (buffer C,
containing 20 mM HEPES [pH 7.9], 0.4 M NaCl, 2 mM EDTA, 1 mM DTT,
and 1 mM PMSF), incubated for 30 minutes at 4°C, and centrifuged at
20 000g for 20 minutes. The supernatants were either used as nuclear
fractions immediately or stored at 80°C until use. The protein concentra-
tion was determined by a Bio-Rad protein assay according to the
manufacturer’s protocol (Bio-Rad Laboratories, Hercules, CA).
Lysates containing 100 g of protein were subjected to 12.5% or 9.4%
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and then were
transferred to Immobilon-P membrane (Millipore, Bedford, MA). The
membrane was incubated with the primary antibody (dilution of 1:1000)
overnight at 4°C and then with a peroxidase-linked secondary antibody
(dilution of 1:2000) for 1 hour at room temperature, and proteins were
visualized by enhanced chemiluminescence.
For detection of MRP1, 100 g crude membranes prepared from Jurkat
and S1T cells and 10 g membrane vesicles prepared from KB/MRP, which
was used as a positive control, were subjected to 7.5% SDS-PAGE, and an
m6 monoclonal antibody against MRP1 was used for MRP1 detection. The
density of the bands for MRP1 was quantified using a charge-coupled
device (CCD) camera (Bio-Rad Laboratories-Segrate, Milan, Italy).
Cell survival by the MTT assay
MT2 (2  104/mL), S1T, and Jurkat cells (1  104/mL) were incubated
either with or without various concentrations of sodium arsenite for the
indicated time in 96-well plates. Ten L MTT solution (5 g/mL) was
added to each well and then the plates were incubated for an additional 4
hours. The MTT formazan precipitate was dissolved in 100 L isopropanol
containing 0.04 N HCl. The plates were shaken for 5 minutes and read
immediately at 570 nm using a model 550 Micro Plate Reader (Bio-Rad,
Hercules, CA).
For chemosensitivity in vitro, MT2, S1T, and Jurkat cells (1  104/mL)
were incubated in culture medium with various concentrations of indicated
drugs at a final volume of 100 L. After 3 days, 10 L MTT was added to
each well and the plates were incubated for an additional 4 hours. Optical
density at 570 nm (OD570) was measured as described.
Apoptosis analysis by FACS
MT2, S1T, and Jurkat cells (1  106) were treated with various concentra-
tions of sodium arsenite for various periods. The cells were harvested,
washed once with PBS, suspended in 50 L PBS, and mixed with 50 L
Coulter DNA-prep LRP (COULTER, Miami, FL), and then 1 mL Coulter
DNA-prep Stain was added. The mixtures were then incubated for 15
minutes at room temperature. The sub-G1 fraction was determined using
a Coulter FACSCAN (Becton Dickinson, San Jose, CA) as previously
described.22
Caspase-3 activity assay
Enzymatic reactions were carried out in the mixture containing 50 g cell
lysate treated by various concentrations of sodium arsenite, interleukin-1
-converting enzyme (ICE)–like enzyme assay buffer (100 mM HEPES
[pH 7.5], 10% sucrose, and 0.1% CHAPS), and 10 mM DTT. The reaction
mixtures were incubated at 30°C for 30 minutes. Next, the 50 M synthetic
fluorogenic substrate, Ac-DEVD-MCA (Ac-Asp-Glu-Val-Asp-MCA), was
added and incubated at 30°C for another 60 minutes. The activity of
caspase-3 was measured at an excitation wavelength of 360 nm and an
emission wavelength of 460 nm using a FP750 microplate fluorescence
reader (Jasco, Tokyo, Japan).
Statistical analysis
All statistical analyses were performed by the Statview 5.0 software
package for Windows (SAS Institute, Cary, NC). For patients with ATL,
differences in the numerical data between the 2 groups were evaluated using
the Mann-Whitney U test. A P value of less than .05 was considered to be
statistically significant.
For the MTT assay, the fluorescence-activated cell-sorting (FACS)
analysis, and the caspase-3 activity, the quantitative data were expressed as
the mean plus or minus standard deviation (SD). Statistical comparisons
were performed using one-way analysis of variance (ANOVA) or the
unpaired Student t test. Differences were regarded as significant when the
probability values were less than .01.
Results
Expression of mRNA for IAP proteins determined by real-time
quantitative PCR or RT-PCR
ATL’s drug resistance is one of the main obstacles to successful
chemotherapy. Kamihira et al15 reported that survivin was promi-
nently and consistently expressed in ATL, thus correlating with the
ATL prognosis. However, the role of other IAP members such as
IAP1, IAP2, and XIAP in the resistance of ATL to chemotherapy is
uncertain. To quantitate the mRNA expression levels of the IAP
family in ATL cells, real-time quantitative RT-PCR was performed.
As shown in Figure 1A, the expression of the survivin gene was
significantly higher (P 	 .01) in acute, chronic, and smoldering
ATL than that in healthy controls. The expression of the survivin
gene in acute ATL was higher than that in chronic and smoldering
ATL (P 	 .05). The expression of the survivin gene in PS3 to PS4
ATL was higher than that in PS0 to PS2 ATL (P 	 .05). The mRNA
levels of cIAP1 and XIAP (Figure 1B-C) did not differ substantially
among the subtypes of ATL and the healthy controls, and between
PS0 to PS2 and PS3 to PS4 ATLs. The expression of cIAP2 was
also detected by RT-PCR, but the expression level in ATL did not
increase significantly more than that in the control (data not
shown). The patients’ age, sex, and white blood cell (WBC) count
of ATL were not correlated with the expression of IAP proteins
(data not shown). These results show that only the survivin gene
was overexpressed in ATL, thereby showing a correlation with the
PS of the patients.
Protein expression of survivin in ATL
We next examined the expression levels of survivin in ATL cells
from 17 patients by Western blotting (Figure 2A), and compared
with the survivin mRNA levels in ATL cells of each patient. As
shown in Figure 2B, the expression level of survivin mRNA was
significantly correlated with that of the protein (r 
 0.516,
P 
 .033). These results suggest that survivin alone is overex-
pressed among the members of the IAP family in ATL, especially in
acute ATL. The survivin expression level was correlated with the
ATL progression (Figure 1A).
Down-regulation of survivin by sodium arsenite in ATL cells
As2O3 was shown to have a therapeutic effect against acute
promyelocytic leukemia (APL) and other types of haemotologic
malignancies by decreasing the expression of Bcl-2 and inducing
4882 CHE et al BLOOD, 15 JUNE 2006  VOLUME 107, NUMBER 12
apoptosis. It was recently reported that As2O3 combined with
interferon  (IFN-) could also induce apoptosis in ATL cells. We
thus investigated whether sodium arsenite can regulate the expres-
sion of survivin in ATL cells. MT2 (Tax-positive), S1T (Tax-
negtive), and a T-cell lymphoma cell line, Jurkat (as a control) cells
were treated with 0, 2, and 5 M sodium arsenite for 1, 2, and 3
days, and the expression of survivin and BCL-2 was detected by
Western blotting. -tubulin was used as a control for protein
loading. The expression of survivin in MT2 and S1T cells
dramatically decreased from 2 days after treatment with 2 and 5
M sodium arsenite (Figure 3A). The relative density of survivin
compared with the untreated controls is shown in Figure 3B.
However, no clear down-regulation of survivin in Jurkat cells was
detected (Figure 3A-B). Sodium arsenite did not down-regulate
Bcl-2 expression in all 3 cell lines used in this study. The RNA level
of survivin was also decreased by sodium arsenite treatment in S1T
cells, but not in Jurkat cells (Figure 3C). These data suggest that
survivin is a target of sodium arsenite in ATL cells. Sodium arsenite
could both dose- and time-dependently down-regulate the survivin
expression at the RNA and protein levels in ATL cells.
Effects of sodium arsenite on cell proliferation
We next examined whether the growth inhibition of ATL cells by
sodium arsenite correlates with the suppression of survivin expres-
sion. MT2, S1T, and Jurkat cells were treated with 0, 0.5, 1, 2, 5,
and 10 M sodium arsenite for 5 to 7 days, and cell proliferation
was measured by an MTT assay. As shown in Figure 4, the growth
of MT2 and S1T cells was inhibited at a dose of 0.5 M sodium
arsenite (Figure 4A-B). However, no significant growth suppres-
sion was observed at a dose of 2 M sodium arsenite in Jurkat cells
(Figure 4C).
The dose-response curves of sodium arsenite for S1T and MT2
cells were compared with that for Jurkat cells. As shown in Figure
4D, MT2 and S1T cells were more sensitive to sodium arsenite than
Jurkat cells. IC50 values (the concentrations of sodium arsenite that
inhibit 50% of cell growth) for MT2, S1T, and Jurkat cells were
2.17 M  0.33 M, 1.99 M  0.03 M, and 10.54 M  0.17
M, respectively. These results suggest that the ATL cell lines MT2
and S1T are sensitive to sodium arsenite even at low concentra-
tions, and the suppression of survivin expression is, at least in part,
involved in the growth inhibition of the ATL cells.
Effects of sodium arsenite on apoptosis
To investigate whether the inhibition of cell proliferation was due
to enhanced apoptosis, the proportion of sub-G1 fraction was
investigated in the presence of 0, 1, 2, 5, and 10 M sodium
arsenite for 1, 2, and 3 days. Sodium arsenite at 1 M did not
increase the proportion of sub-G1 fraction, but the proportion of
sub-G1 fraction both dose- and time-dependently increased at 2, 5,
and 10 M in MT2 and S1T cells (Figure 5A-B). However, the
increase in the proportion of the sub-G1 fraction of Jurkat cells
treated with the same concentrations of sodium arsenite was less
than that of the ATL cells (Figure 5C). Sub-G1 fraction in MT2 and
S1T cells treated with various concentrations of sodium arsenite for
3 days was significantly higher than that in Jurkat cells (P 	 .01)
(Figure 5D). This result suggests that sodium arsenite inhibits the
growth of ATL cells by inducing apoptosis.
Effects of sodium arsenite on caspases activation in ATL cells
Survivin was shown to bind directly with caspase-3 to inhibit the
caspase activity in human cells exposed to apoptotic stimuli. We
Figure 1. IAP family mRNA expression. A quantitative RT-PCR analysis for survivin
(A), cIAP1 (B), and XIAP (C) is shown in patients with acute, chronic, and smoldering
ATL and in a healthy control (left), low PS and high PS (right). Each mRNA expression
level was normalized on the basis of the GAPDH mRNA expression and expressed
relative to the mRNA level in a healthy control. Boxes correspond to the interquartile
range. Lines in the boxes represent median values. The vertical lines represent the
10th and 90th percentiles, and the circles represent the outliers. Differences were
analyzed by Mann-Whitney’s U test.
Figure 2. Protein expression of survivin in ATL. Whole-cell lysates (50 g protein)
from patients with ATL were separated by 12.5% SDS-PAGE and then transferred to
a PVDF membrane. The transferred proteins were reacted with antibody against
survivin (A) as described in “Patients, materials, and methods.” *Concentrations of
survivin protein and mRNA are expressed relative to the survivin protein and mRNA
levels in control normal cells, which were assigned values of 1. (B) A comparison
between the survivin mRNA level (y-axis) and the protein expression level (x-axis) in
17 patients with ATL. The survivin mRNA level correlated with the protein level
(r 
 0.516, P 
 .033).
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investigated whether caspases-3 are activated in ATL cells by
treatment with sodium arsenite. As shown in Figure 6, the
caspases-3 activity increased in MT2 (Figure 6A) and S1T (Figure
6B) cells treated with 2 and 5M of sodium arsenite. The increased
cleavage of PARP was also detected in MT2 and S1T cells treated
with sodium arsenite (Figure 3A). These results indicate that the
down-regulation of survivin by sodium arsenite thus causes
caspase-3–dependent cell death.
Decreased expression of survivin through the surpression
of NF-B activity by sodium arsenite
NF-B is known to be constitutively activated in ATL. Either a
Tax-dependent or Tax-independent mechanism of activation of the
NF-B pathway is crucial for the proliferation of malignant cells,
protection from apoptosis, and drug resistance in ATL. Tax
regulates the expression of survivin through NF-B pathway, and
the combination of As2O3 and IFN- decreases the activation of
NF-B in ATL cells. We therefore investigated the levels of nuclear
p50 and p65 in ATL cells treated with sodium arsenite. As shown in
Figure 7A, sodium arsenite increased the level of IB- in MT2
cells. p50 and p65 in the nucleus of MT2 cells was decreased by
sodium arsenite in a dose- and time-dependent manner. Cytosolic
and nuclear survivin decreased in accordance with the decrease of
nuclear p50 and p65. Although no significant decrease of p50 was
seen in the nuclei of S1T cells, p65 in the nuclei dose-dependently
decreased by sodium arsenite (Figure 7B). These results suggest
that sodium arsenite suppress the expression of survivin by
preventing IB- degradation and the translocation of NF-B into
the nuclei.
Expression of MRP1 and the resistance to sodium arsenite
in Jurkat cells
To elucidate the molecular basis for the difference in sensitivity to
sodium arsenite between Jurkat and S1T cells, we examined the
Figure 3. The effects of sodium arsenite on the survivin expression in ATL cells.
(A) MT2, S1T, and Jurkat cells were incubated in the presence of 2 or 5 M arsenic
trioxide for 24, 48, or 72 hours. Whole-cell lysates (100 g protein) were prepared
and separated by 12.5% SDS-PAGE and transferred to a PVDF membrane. The
transferred proteins were reacted with the antibody against survivin, Bcl-2, or PARP
as described in “Patients, materials, and methods.” As an internal control, -tubulin
expression was detected. (B) The quantification of the survivin levels in MT2, S1T,
and Jurkat cells. The relative density of the bands for survivin obtained by a
densitometric analysis and -tubulin was used to normalize the respective intensities.
(C) S1T and Jurkat cells were treated with sodium arsenite at the indicated
concentration and time. Total RNA was then subjected to RT-PCR using primers
specific for the amplification of survivin. -actin expression was examined as an
internal control to ensure the RNA integrity and proper amplification.
Figure 4. Growth inhibition of MT2, S1T, and Jurkat cells by sodium arsenite.
Proliferation of MT2 (A), S1T (B), and Jurkat (C) cells in the absence or presence of
the indicated concentrations of sodium arsenite was assessed by MTT assay. (D) The
sodium arsenite toxicity in MT2, S1T, and Jurkat cells was determined by an MTT
assay. The points represent the means of triplicate determinations, while the bars
show SD.
Figure 5. Effects of sodium arsenite on the proportion of sub-G1 fraction of
MT2, S1T, and Jurkat cells. MT2, S1T, and Jurkat cells were treated with 0, 1, 2, 5, or
10 M sodium arsenite for 1, 2, or 3 days. The cells were then stained by propidium
iodide (PI) and analyzed by flow cytometry. The proportion of sub-G1 fraction of MT2
(A) and S1T (B) was higher than that of Jurkat cells (C) under the indicated
concentrations of sodium arsenite and the indicated time. Each column and bar
represents the mean  SD of 3 independent experiments. (D)The sub-G1 fraction of
MT2, S1T, and Jurkat cells treated with sodium arsenite for 3 days was compared.
Each column and bar represents the mean  SD of 3 independent experiments.
*P 	 .01.
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expression levels of MRP1 in these cells. MRP1 is involved in
arsenite resistance and supposed to transport arsenite conjugated
with glutathione. As shown in Figure 8A, MRP1 was expressed in
both Jurkat and S1T cells, but the expression level of MRP1 in
Jurkat cells was about 3-fold higher than that in S1T cells. The
higher molecular weight of MRP1 in S1T cells might be caused by
a variation in glycosylation of MRP1 in the cells.
As shown in Figure 8B, Jurkat cells were about 4-fold more
resistant to sodium arsenite than S1T cells (IC50 values of S1T and
Jurkat cells for sodium arsenite were 1.99 M  0.03 M and 9.73
M  0.71 M, respectively). An inhibitor of MRP1, AG-A alone
had no cytotoxic effect at 30 M and decreased the IC50 value of
Jurkat cells for sodium arsenite to 4.03 M  0.04 M. A specific
inhibitor of MRP1, MK571 at 30 M completely abolished the
difference in sensitivity to sodium arsenite between the 2 cell lines.
These findings suggest that the difference in sensitivity to sodium
arsenite between Jurkat and S1T cells is attributed to the different
expression levels of MRP1 in these cells.
Discussion
Patients with acute- or lymphoma-type ATL have a poor outcome,
with a median survival of about 6 months for acute-type and 10
months for lymphoma-type; the expected 4-year survival is only
about 5%. Combination chemotherapy regimens, especially those
for the treatment of aggressive non-Hodgkin lymphoma or acute
lymphoblastic leukemia, have little effect on ATL. The poor
outcome might be due to multidrug resistance in ATL cells.
Overexpression of P-gp, MRP-1, and LRP tend to be common
features of the malignant cells, and they confer intrinsic and
acquired drug resistance on the cells. Another important mecha-
nism of the resistance to apoptosis-inducing anticancer agents is
the failure to activate apoptosis. Members of the IAP family are
also overexpressed in many tumors and leukemia, and they also
inhibit apoptosis. In order to find out the specific target for ATL
therapy, we investigated the expression levels of the members of
the IAP family, the survivin gene, IAP1, IAP2, and XIAP, in ATL
cells from patients using real-time PCR or RT-PCR. Among them,
survivin alone was overexpressed in ATL, especially in acute-type
ATL. The expression level of survivin in poor PS was higher than
that in good PS.
Survivin is broadly expressed in embryonic and fetal organs,23
but it becomes undetectable in most terminally differentiated
normal tissues.24 Survivin was overexpressed in the majority of
human tumor types. In gene-profiling studies, survivin was identi-
fied as the fourth “transcriptome” expressed in the most common
human cancers, but not in normal tissues.25 Retrospective trial
studies suggest that the expression level of the survivin gene
contributes to the clinical outcome of tumors, including an
abbreviated overall survival, increased rates of recurrences, resis-
tance to therapy, and reduced apoptotic index.26 Recent studies
using real-time PCR showed that high expression levels of survivin
mRNA were a risk factor for prognosis of ATL in the clinical
setting.15 These results are consistent with our results in this study.
There are some reports regarding the relationship between
survivin expression and sensitivity to anticancer agents. Forced
overexpression of survivin increased the resistance to paclitaxel in
prostate cancer cell lines. The inhibition of survivin sensitizes
prostate cancer cells to paclitaxel-induced apoptosis through
caspase-dependant mechanism in vitro and in vivo.27 Down-
regulation of survivin expression with ribozyme or small interfer-
ing RNA (siRNA) increased sensitivity to topotecan and adriamy-
cin in JR8 melanoma cell line and HL-60/ADR cells.28,29 We have
knocked down survivin in KB-3-1 cells using siRNA and found
that the cells with the decreased level of survivin were more
sensitive to doxorubicin, etoposide, and sodium arsenite than were
the control KB-3-1 cells (data not shown). Survivin is an attractive
therapeutic target in cancer for its differential expression in tumors
versus normal tissues, and for its role in maintaining cancer-cell
Figure 6. The activities of caspase-3 in MT2 and S1T
cells in the absence or presence of sodium arsenite.
The caspase-3 activity was measured in the cell lysates
using the specific substrate Ac-DEVD-MCA. The data are
expressed in arbitrary units. Each value represents the
mean of 3 independent experiments. Bars indicate SD.
*P 	 .01.
Figure 7. The effect of sodium arsenite on the levels
of IB-, NF-B, and survivin in nuclear and cytoso-
lic fraction from MT2 and S1T cells. (A) MT2 cells were
treated with sodium arsenite at the indicated concentra-
tions; nuclear and cytosolic fractions were prepared at
the indicated time. Nuclear protein (50 g) was subjected
to Western blotting using the antibody against p50, p65,
or survivin. Cytoplasmic fraction (100 g of protein) was
subjected to Western blotting using the specific antibody
against IB- or survivin. -tubulin expression was used
as a loading control. NE indicates nuclear extract; CE,
cytoplasmic extract. *Nonspecific band. (B) p50 and p65
in the nucleus and cytoplasmic survivin in S1T cells
treated with sodium arsenite in the indicated concentra-
tion, and time was measured by Western blot as in
panel A.
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viability.25 A survivin-based therapy would be effective in remov-
ing the general cell-viability machinery exploited by cancer cells
and it is also expected to have less side effects since survivin is not
detected in most normal tissues. Targeting survivin with antisense
oligonucleotides,26 ribozymes,28 or expression of dominant-
negative mutants30 resulted in caspase-dependent cell death and
suppression of tumor growth in vivo. However, it remains difficult
to apply these approaches to ATL therapy so far. In this study, we
found, for the first time, that trivalent arsenite, sodium arsenite,
could down-regulate the expression of survivin at RNA and protein
level in ATL cells. Sodium arsenite may provide a new avenue to
suppressing survivin, which is an attractive target for treatment of
patients with ATL.
As2O3 is very effective in the treatment of APL, which carries
the t(15;17) translocation involving the RAR- and PML genes.31
As2O3 could also induce apoptosis in breast cancer, esophageal
carcinoma, multiple myeloma, and ATL.32-35 It has recently been
shown that As2O3 synergizes with IFN- to induce cell-cycle arrest
and apoptosis in cells infected with HTLV-1, and in the adult T-cell
leukemia and lymphoma cells.36 Our study showed that sodium
arsenite alone could suppress the growth and induce apoptosis in
ATL cells. Sodium arsenite suppressed the growth of ATL cells at
low concentrations and induced apoptosis of ATL cells at a
relatively high concentration (2 M), at which the expression of
survivin was down-regulated.
Survivin plays an important role in the suppression of mitochon-
dria-dependent apoptosis by either directly or indirectly inhibiting
the activity of caspases. Complexes between survivin and caspase-
9,37 caspase-3, or caspase-738 have been demonstrated. Survivin
has also been shown to be associated with Smac/DIABLO,39 a
proapoptotic protein that is released from mitochondria and it
prevents the inhibitory effect of IAPs on caspase activation.
Moreover, apoptosis induced by dominant-negative survivin mu-
tants have the characteristics of mitochondria-dependent apoptosis
with cytochrome c release and caspase-3 activation.40 These
findings suggest that survivin protects apoptosis by interacting with
Smac/DIABLO and caspase-9. In the present study, caspase-3 was
activated by sodium arsenite. It is probable that sodium arsenite
induced mitochondria-dependent apoptosis by decreasing the ex-
pression level of survivin in ATL cells.
NF-B is known to be constitutively activated in ATL. The
Tax-dependent or Tax-independent activation of the NF-B path-
way is crucial for proliferation, protection from apoptosis, and drug
resistance in adult T-cell leukemia and lymphoma. The most
common p50-RelA (p65) dimer, “specifically” known as NF-B, is
more abundant and controls the expression of more genes than any
other heterodimers or homodimers. NF-B exists as an inactive
cytoplasmic complex, predominantly made up of p50-p65, and
bound to IB-, an inhibitory protein of the NF-B. Recently,
El-Sabban et al41 showed that IFN-/As2O3 treatment significantly,
and As2O3 alone slightly decreased the expression of the viral
transactivator protein Tax and repressed the activation of NF-B
pathway. As2O3 induced apoptosis of HL-60 cells by repressing
the constitutive activation of NF-B.42 Moreover, Tax induced
survivin expression through NF-B pathway.43 p50 and RelB
were bound to the NF-B binding site in the survivin promoter
between 354 and 345.43 Tax transactivated the survivin
promoter through this NF-B binding site. Our results showed
that the level of p65 and p50 in nuclei was decreased, while the
level of cytoplasmic IB- was increased by treatment with
sodium arsenite in Tax-expressing MT2 cells. This was consis-
tent with the studies of El-Sabban et al41 and Kawakami et al.43
The NF-B activity in the cells that were not infected with
HTLV-1 was also repressed by As2O3.42 In accordance with this
report, we found that sodium arsenite down-regulated the
expression of survivin through the inhibition of NF-B pathway
in S1T cells that did not expess Tax. Sodium arsenite might
suppress the NF-B activity by repressing the p65 translocation
to nuclei, but not through Tax.
Sodium arsenite down-regulated the expression of survivin, but
not of Bcl-2. Since there are a number of genes besides survivin
and Bcl-2 that are up-regulated by NF-B and involved in
facilitating tumor cell survival,44,45 further study is needed to
elucidate whether the down-regulation of these genes is also
involved in apoptosis and decreased cell growth of ATL cells
caused by sodium arsenite.
In this study, the concentration of sodium arsenite required to
inhibit the growth of ATL cells in vitro was more than 0.5 M and
the concentration required to induce apoptosis was more than 2
M. These concentrations appear to be beneficial and safe for
clinical use in patients with ATL. The plasma arsenic rapidly
reached a mean maximum serum level of 6.85 M (range,
5.54-7.30 M) at 4 hours after intravenous injection of 10 mg
As2O3.46 A recent phase 2 trial in 7 patients with a relapsed or
refractory ATL has shown that the combination of IFN- and As2O3
is a hopeful therapy for ATL.47 These preliminary results highlight
that the treatment of ATL with As2O3 and IFN- is feasible and has
a clear antileukemic effect, even in patients with refractory disease.
Further study is needed to clarify whether the combination of
arsenite and IFN- can down-regulate survivin more effectively,
and whether arsenite can enhance the sensitivity of ATL cells to
conventional anticancer agents.
T-cell leukemia Jurkat cells, which were used as a control, were
more resistant to sodium arsenite than ATL cells. MRP1 is a
member of the ATP binding cassette (ABC) superfamily of
transport proteins and is involved in arsenite resistance. We have
previously demonstrated the clinical significance of MRP1 expres-
sion and that high MRP1 expression correlated with short survival
in patients with acute-type and lymphoma-type ATL.9 The expres-
sion level of MRP1 in Jurkat cells was about 3-fold higher than that
in S1T cells, and MK571, a specific inhibitor of MRP1, abolished
the difference in sensitivity to sodium arsenite between the 2 cell
Figure 8. Expression of MRP1 and the resistance to sodium arsenite in Jurkat
cells. (A) Crude membranes (100 g protein) were prepared and separated by 7.5%
SDS-PAGE and transferred to a PVDF membrane. The transferred proteins were
reacted with an antibody against MRP1 as described in “Patients, materials, and
methods.” KB/MRP membrane vesicles (10 g) were used as a positive control. (B)
Jurkat and S1T cells were incubated with the indicated concentrations of drugs for 72
hours, and cell viability was determined by the MTT assay. The points represent the
means of triplicate determinations, and the bars show SD.
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lines. Since MRP1 transported inorganic arsenic as a tri–
glutathione (GSH) conjugate,48 we examined the GSH level in the
cells and found that the level of GSH in Jurkat cells was similar to
that in S1T cells (data not shown). These findings suggested that
MRP1, at least in part, might be responsible for the decreased
sensitivity to sodium arsenite of Jurkat cells.
In this study, we proved for the first time that arsenite could
down-regulate survivin by repressing NF-B activation in ATL
cells regardless of the Tax expression. Our findings provide a
rational basis for the new therapy for ATL using arsenite.
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